Cantargia (CANTA) BioStock Life Science Summit 2026 summary

IL1RAP platform and portfolio

• IL1RAP co-receptor links IL-1, IL-33 and IL-36 pathways; blocking it can target three inflammatory pathways through one intervention.

• Library includes 500 IL1RAP-targeted clones for developing antibodies, bispecifics and ADCs, plus analytical use; two clinical candidates have been developed.

• Otsuka deal for CAN10 totaled $613 million in potential bio-dollar value, including $33 million upfront; a new bispecific also targets IL1RAP, with its second target planned for disclosure near Christmas 2026.

Hematologic programs

• Nadunolimab is designed to block IL-1-driven leukemic stem-cell survival and engage natural immune defenses while sparing normal hematopoietic stem cells.

• In the MD Anderson-sponsored trial data cut in June 2026, 7 of 10 MDS patients responded; AML response rate was 33%, including one complete response among nine patients discussed in Q&A.

• Phase I-B is complete with safety described as excellent; one grade 3/4 event, an infusion reaction, was considered likely related to nadunolimab. MD Anderson plans to enroll ~40 patients.

• MDS standard-of-care response rates were cited at 10%-30%; 30% of patients progress within 6-12 months. Durability of nadunolimab response remains to be established.

• ASH oral presentation is scheduled for December 2026; high-level Phase II-A results in MDS and AML are expected in mid-2027.

Pancreatic cancer program

• Daraxonrasib became second-line standard of care after approval in August 2026; first-line treatment remains chemotherapy.

• Prior nadunolimab-plus-chemotherapy results showed 13.2 months overall survival versus 6-7 months with chemotherapy alone; a Phase I-B combination study with daraxonrasib is planned.

• RAS inhibition targets tumor signaling, while nadunolimab blocks IL-1 pathways; preclinical combination models showed tumor-microenvironment disruption and return of T and NK cells.

• Planned Phase I-B study will assess safety and bioavailability in ~15 patients progressing after first-line standard of care, with initiation targeted for Q1 2027.